SEARCH

SEARCH BY CITATION

Keywords:

  • canine;
  • diagnosis;
  • immunity;
  • transmissible venereal tumour;
  • treatment

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

Canine transmissible venereal tumour (CTVT) is a contagious venereal tumour of dogs, commonly observed in dogs that are in close contact with one another, or in stray and wild dogs that exhibit unrestrained sexual activity. CTVT represents a unique, naturally transmissible, contagious tumour, where the mutated tumour cell itself is the causative agent and perpetuates as a parasitic allograft in the host. Clinical history, signalment and cytological features are often obvious for establishing a diagnosis though biopsy and histological examination may be needed in atypical cases. Most cases are curable with three intravenous injections of vincristine sulphate at weekly intervals. The role of stray and wild dogs makes the disease difficult to control and necessitates sustained animal birth control in stray dogs along with prompt therapy of the affected dogs. This review captures the manifold developments in different areas embracing this fascinating tumour, including its biology, diagnosis and therapeutic alternatives.


Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

Canine transmissible venereal tumour (CTVT), also called transmissible venereal sarcoma, Sticker's sarcoma, venereal granuloma and infectious sarcoma, is a contagious venereal tumour of dogs. Considering the abbreviative similarity with cardio-thoracic vascular surgery (CTVS), it is better to reserve the use of the abbreviation CTVT for this tumour. First described by Hujard in 1820 in Europe,[1] it is most commonly observed in dogs that are in close contact with one another, or in stray and wild dogs that exhibit unrestrained sexual activity. In 1876, first ever in the history of oncology, the Russian veterinarian Novinsky demonstrated the transplantation of the tumour from one dog to another by infecting them with tumour cells.[2] So far, only three naturally transmissible, contagious tumours are known in mammals, viz. CTVT, the Tasmanian devil facial tumour disease (DFTD) and a similar tumour of Syrian Hamsters.[3] Spanning over almost two centuries, CTVT continues to attract the attention of many researchers, as it reflects ever new and often surprising paradigms and offers to have something of everyone's interest. This review captures the manifold developments in different areas embracing this fascinating tumour, including its oncobiology, diagnosis and therapeutic alternatives.

Geographical distribution

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

CTVT has been reported from all continents of the world except Antarctica.[1, 2] It is uncommonly reported from North and Central Europe and from North America, mainly because of the control of stray dog populations, thorough prebreeding examinations and effective treatment of clinical cases. Baring few exceptions, CTVT remains enzootic in the rest of the world, including Puerto Rico, Papua New Guinea and south-west France.[4, 5] CTVT is more common in tropical and subtropical regions, particularly in the southern United States, Central and South America, south-east Europe, Ireland, China, the Far East, Middle-East and parts of Africa.[4-6] In Bahamas, Japan and India, it is the most common tumour of dogs.[6-8] Das and Das[2] reported a homogeneous distribution of the neoplasm across varying geo-climatic zones in India.

Aetiology and transmission

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

Although Novinsky's success at transplanting the tumour in 1876 provided some early cues, it was for Cohen[9] to conclusively prove that the mutated tumour cell itself was the causative agent. The transmission of the tumour needs viable tumour cells as cells that were frozen, heated, treated with glycerin or desiccated failed to produce the disease.[10] An intact epithelial barrier in susceptible dogs disallows the natural transmission of the tumour; the tumour can be naturally transmitted only across abraded mucosa where epithelial continuity has been breached. Tumour cells are exfoliated and transplanted during coitus from animal to animal and perpetuate themselves like any other heterologous, mono-cellular organism. However, Marcos et al.[11] reported a unique case of TVT in a sexually immature, 11-month-old, virgin bitch showing entirely cutaneous lesions without any mucosal involvement, also suggestive of transmission from the dam to the pup during social interactions such as grooming and other maternal behaviour. In natural transmission, the number of tumour cells undergoing transplantation may also be important as it has been shown that only about 13% of the transplanted cells are able to survive until the infection is established in the recipient.[12] The tumour may also spread through licking, scratching, biting or sniffing tumour-affected areas. CTVT, thus, represents an infectious cell line transmissible as a naturally occurring allograft.[13] Experimentally, Karlson and Mann[14] succeeded in passaging the tumour through 40 generations of dogs over a period of 17 years with no changes in the histopathology of tumour during the passage.

This ‘naturally occurring allograft’ has become a true pathogen that defies natural transplantation barriers.[15] Murgia et al.[16] employed microsatellite and dog leukocyte antigen (DLA) analysis to conclude that the CTVT cells arose around 200–2500 years back in wolves or in some old East Asian dog breed such as the Shih Tzu. Cancer cells rapidly accumulate mutations and become genetically instable; CTVT presents a new paradigm as the study showed that soon after emergence, the tumour cell underwent some drastic genetic re-arrangements following which the tumour cell has been passed on with little genetic variation. The study also suggested that CTVT must be regarded as a special case of somatic chimerism. However, Rebbeck et al.[17] employed microsatellite analysis to conclude that TVT is more than 6000 years old, and using sequence analysis of RPPH1 gene they also suggested its origin from a dog or wolf during the first domestication of dogs. Rebbeck et al.[18] further showed that the cancer has periodically acquired mitochondria from its host as the TVT mitochondria tend to degenerate because of high mutations.

Excitating factors

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

Intact dogs form the high-risk group during periods of maximal sexual activity when females exhibit the signs of oestrus. The disease usually (80%) occurs in animals of reproductive age (2–8 years old) and less often at older ones.[1, 6, 19, 20] Females are infected more often than males (64.5 and 35.5%, respectively) because one infected male often mates with numerous females, in free range or stray group and also in kennels.[1, 21, 22] On the basis of social behaviour, the high-risk groups include the habitually yard-escaping dogs (75.5%), guard dogs (41.3%) and hunting dogs (41.5); CTVT is rare in well-supervised home-kept companion animals (4%), occurring only after an escape eventuating into an unwanted copulation event.[1] Incidence of extra-genital tumours may be higher in males owing to the breeding behaviour of the male. Metastatic events are more numerous in the male dogs.[23, 24]

The tumour occurs naturally only in dogs; however, experimental infection (heterotransplantation) has been established in other canine species, such as foxes, coyotes and jackals as well as in immunodeficient mice models, such as athymic and NOD/LtSz-SCID mice.[12, 25, 16, 26] Any well-established heritable breed-related prevalence is not known[2] although Kabuusu et al.[27] observed an increased incidence of TVT in Pothounds as compared with other dog breeds in Grenada, West Indies. Molecular studies suggest that the insertion of a transposable element viz. long interspersed nuclear element (LINE) -1 near the 5′ end of the first exon of the c-myc oncogene in the germline might represent a predisposition to develop CTVT after exposure to an oncogenic agent.[16, 28]

Clinico-pathological features

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

The tumour is cauliflower-like, pedunculated, nodular, papillary or multilobulated. It ranges from a small nodule (5 µm) to a large mass (up to 15 cm) and is firm, though friable. The surface is often ulcerated and inflamed[29] and may be haemorrhagic and infected (Figs 1 and 2A). The tumour may be solitary or multiple and is almost always located on the external genitalia, although it may occur in adjacent skin and oral, nasal and conjunctival mucosae. Incidence varies from relatively high in some parts of the body to rare in others. The tumour may arise deep in the prepuce or vagina and be difficult to see. This may lead to misdiagnosis if bleeding is confounded with oestrus, urethritis, cystitis or prostatitis.[30, 31] In female dogs, the neoplastic lesions are usually located at vestibule (95.6%) and less often at the vagina (44.5%) or invading the vulvar lips (18.6%). Main lesions are almost always present at the junction of the vestibule and vagina, perhaps because of the high pressure exerted on this area during the mating act. In male dogs, neoplastic lesions are located on the more caudal part (bulbus glandis, 81.5%; Fig. 2A) and less often on the shaft (pars longa glandis, 25.9%) or the tip (9.9%) of the glans penis.[1] Occasionally lesions may be present in other parts of the body without any genital involvement;[6, 32, 33] primary intranasal transmissible venereal tumour in the dog has been reported by Papazoglou et al.[34] In cases with extra-genital localization of the TVT, clinical diagnosis is usually more difficult because TVTs cause a variety of signs depending on the anatomical localization of the tumour, e.g. sneezing, epistaxis,[34] epiphora, halitosis and dental fistula, exophthalmos, skin bumps, facial or oral deformation along with regional lymph node enlargement.[30] Infrequently, the tumour cells may be parasitized by Leishmania, representing an alternative mode of transmission of canine leishmaniasis where the two diseases co-exist.[35-37]

image

Figure 1. Fulminating TVT lesion in a mongrel female dog with pan anogenital invasion by the tumour causing gross ulceration and haemorrhages.

Download figure to PowerPoint

image

Figure 2. TVT and its response to vincristine therapy in a male Rampur hound. (A) Photograph of the case as presented on the first occasion; a large TVT mass growing deep under the bulbus glandis looms over the shaft of the penis. The lesions are spontaneously haemorrhagic with inconsistent clots. (B) One-week post-treatment with the first dose of vincristine, the animal presents appreciable reduction in lesions. Compare the change in the surface appearance; the lesions appear pale and less haemorrhagic. (C) After its second week of vincristine therapy, gross reduction in the lesion is evident with adequate visibility of the bulbus glandis upon retraction of the prepuce. (D) By the end of the third week of vincristine treatment, the tumour has regressed with very little granulomatous tissue remaining at the base of bulbus glandis. The presence of such minimal lesions does not require continuing treatment with vincristine sulphate.

Download figure to PowerPoint

Initially, the tumour grows rapidly presenting a brightly sanguine colouration, commonly associated with the oozing of a haemorrhagic fluid (94.6%), to be followed by protrusion of the neoplastic lesions (31.3%) and deformation of the external genitalia (30.4%). The peculiar odour of the neoplastic lesions discharge (27.2%), which after secondary bacterial infection becomes particularly unpleasant, and the excessive licking (5.8%) of the genitalia are also commonly noticed. Less commonly observed symptoms include dysuria (5.4%), weakness (4.6%), ulcers in the perineum area (2.1%), anorexia (1.7%), constipation (0.8%), paraphimosis (0.8%), mating refusal (0.4%) and weight loss (0.4%).[1] Dogs with transmissible venereal tumours are at a high risk of having bacteriuria likely owing to obliteration of the urethral orifice by the tumour leading to urine retention.[38] Few cases have also been recorded where this neoplasm has caused actual mechanical obstruction to the flow of urine or has produced dystocia in whelping females.[4]

The clinical findings are less striking in male dogs and the disease is consequently less easily perceptible than in females. Clinical and laboratory findings suggest that the general health of affected animals is not impaired unless the lesions turn necrotic and infected or occlude the urethral orifice, or metastasis occurs. Haematocrit values are slightly lower than normal in less than 10% of the affected dogs, but no severe anaemia is found. In about 30% of the cases a mild-to-moderate leukocytosis may be apparent, probably caused by the inflammation of the tumour surface.[1]

CTVT undergoes a predictable cycle: an initial growth phase of 4–6 months (P phase), a stable phase and a regression phase (R phase),[39] although not all tumours will regress. Progressing tumours are characterized by higher mast cell counts and microvessel counts at the invasive edges of the tumours.[40] Regressing tumours contain higher numbers of lymphocytes, most of which are T cells. P-phase tumours consist of round cells with microvilli, whereas those in stable phase consist of cells undergoing transition from round cells to spindle-shaped fibroblasts. Regressing tumours have spindle-shaped cells with intracellular collagen bundles within vacuoles.[41] Mitotic figures, telomerase activity, proliferating cell nuclear antigen (PCNA) positive rate and argyrophilic nucleolar organizer region (AgNOR) content is higher during P phase.[42] Metastasis is uncommon (5%); when it occurs, it is usually to the regional lymph nodes including inguinal and external iliac lymph nodes but may also be seen in the kidney, spleen, liver, eye, tonsils, brain, pituitary, skin and subcutis, maxillary bone, mesenteric lymph nodes and peritoneum.[1, 2, 43, 44]

Diagnosis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

Diagnosis is established based on anamnesis, signalment, clinical findings, cytology and histology; cytogenetic and molecular techniques may also be applied. Paterson et al.[45] compared the uptake of 67Gallium and 45Calcium in lactating bitches and found that concentrations in individual pieces of a lactating mammary gland at 5 h after injection were correlated; however, no such correlation was seen in multiple samples of a transmissible venereal tumour. Increased concentration and longer retention of 67Gallium citrate in mammary CTVT was observed. The differential uptake of such radionuclides by CTVT tissue may be of diagnostic importance. Also, the use of a contrast agent (NC100100) during transrectal ultrasonography has been shown to increase the accuracy of lesion detection from 67 to 87%.[46]

TVT cells may be collected by fine-needle aspiration of the tumour mass; cells may also be detected in free-catch samples of urine. Cytologically, TVT cells have a very distinct appearance[47] (Fig. 3). They are round to oval in shape and often contain mitotic figures, with chromatin clumping and one or two prominent nucleoli. The most striking cytological finding is the presence of multiple clear cytoplasmic vacuoles. Vacuolation increases during early stages of regression as TVT cells undergo degeneration. During degeneration, amounts of endoplasmic reticulum and ribosomes also increase, as does swelling and vacuolation of mitochondria. Degenerating cells often contain numerous membrane-bound granules and clusters.[48] Cytology provides a better evidence of CTVT as compared with histology. The histologic appearance of transmissible venereal tumour may be difficult to distinguish from other round cell tumours such as histiocytoma, lymphosarcoma or mast cell tumours; especially so when the tumours involve extra-genital locations. Upon reticulin staining, TVT cells show invasion of the inter-alveolar spaces by reticulum fibres, characteristic of alveolar soft-part sarcoma.[49]

image

Figure 3. Numerous round to oval cells are present with multivacuolated cytoplasm. Many cells show more than one nucleoli; the granular appearance of the karyoplasm due to chromatin clumping and increased nucleus:cytoplasm ratio are other cytological features of TVT.

Download figure to PowerPoint

For the diagnosis of TVT by immuno-histochemistry a panel of antibodies is required. TVT shows the immuno-histochemical staining characteristics of histiocytic cells and the differentiation between these two tumour types should, therefore, be based on clinical and histopathologic criteria. The tumours stain with antibodies against vimentin, lysozyme, α-1-antitrypsin and glial fibrillary acidic protein, and are negative for keratins, S100 and muscle markers.[50, 51]

Cytogenetics is of decisive advantage in the definitive diagnosis of the CTVT because of the highly significant karyotypic differences that exist between normal and cancerous cells. Although the normal chromosome number for the dog is 78 and all but two are acrocentric, the chromosome count in TVT cells is 59 (range 57–64) of which 15 or 17 are metacentric and 42 or 40 are acrocentric whereas the total amount of DNA remains close to normal.[51, 52] The same chromosomal pattern is also maintained in cell culture.[53] The sex chromosome complement is XO. Microarray-based comparative genomic hybridization analysis suggests that TVT has accumulated these non-random chromosome copy number aberrations that are naturally distributed widely throughout the dog genome.[54]

Molecular biology can also be useful in the diagnosis of canine TVT. Palker and Yang[55] succeeded in identifying and characterizing a 70 kDa, temperature and pH labile TVT-specific antigen. Later, Yang et al.[56] also reported a TVT-associated antigen from the sera of affected dogs. The c-myc oncogene is re-arranged in this tumour by insertion of a 1.5 kbp transposable sequence, known as the long interspersed element (LINE), 5′ to the first exon. Analysis of TVT samples from around the world has revealed that in all tumours the insertion of the same LINE occurs in the vicinity of the c-myc gene, and a PCR amplification of the DNA segment covering the mutation area is of diagnostic importance.[28, 57] Heat shock proteins (HSPs) 60 and 70 are potential markers for TVT, and HSP 60 appears to be involved in CTVT regression.[42] Choi and Kim[58] identified a point mutation of the tumour suppressor protein p53 (T963C) resulting in the change of amino acid (Phe–Ser) in TVT cases. Vázquez-Mota et al.[59] concluded that this mutation did not participate in the clonal origin of the tumour, but was acquired at a later stage. Further, TVT tissue from bitches lacks surface oestrogen receptor-α expression.[60]

Prognosis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

The prognosis for total remission is good, unless metastatic involvement of the central nervous system or eye is present. TVT is antigenic in the dog and the course of the disease is markedly influenced by the immune status of the dog. In healthy, immuno-competent, adult dogs, the tumour regresses spontaneously after a period of logarithmic growth, and the development of tumour immunity prevents successive occurrences. Das and Das[2] recorded that the chances of self-regression in tumours over 9 months of age were remote. The poor prognosis in TVT correlates with an increase of the Ag-NOR proteins in the nucleus of TVT cells.[61] A strong intensity of stromal hyaluronan and a high proportion of hyaluronan-positive tumour cells are significantly associated with progressing tumours.[62]

Immunity

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

Immunological studies have established that TVT is antigenic in the dog as specific antibodies can be demonstrated in circulation as well as on the surface of the tumour cells, and the immune response against the tumour plays a major role in determining the course of the disease.[63, 64] In most adult dogs, the tumour regresses spontaneously after a period of logarithmic growth; after complete regression, the development of tumour immunity prevents successive occurrences. Spontaneous regression is due to the formation of immunoglobulin (Ig) G in the sera of dogs after about 40 days of tumour growth.[65] Upon experimental rechallenge, tumours are detected on the third day, begin to regress on the 9th day and disappear on approximately the 15th day after the secondary transplantation.[66] Newborn pups from immune dams are more resistant towards development of the tumour and exhibit faster remission. In contrast, the tumour progresses to ulceration and metastasis in the immunologically incompetent or compromised host.[2] Lymphocytes from dogs in which TVT has regressed are cytotoxic to TVT cells; sera of such dogs mediate antibody-dependent cellular cytotoxicity with normal dog lymphocytes on TVT cells.[67]

CTVT has evolved several mechanisms to dodge the host immune response. The tumour cells downregulate the expression of their DLA genes that encode for markers which identify the cell. While DLA class II expression is completely inhibited, some expression of DLA class I genes is allowed up to 10%.[16] This is of strategic importance for the tumour to evade the host immunity. Complete masking of the class I DLA tends to activate natural killer cell activity; a low background level of class I expression effectively prevents this activation while making the cells virtually invisible to the host immune system. CTVT cells also secrete transforming growth factor (TGF)-β1 to suppress the host immune system. The TGF-β1 induced immunosuppression is antagonized by interleukin (IL)-6 and IL-15.[68, 69] During tumour regression host IL-6, derived from tumour infiltrating lymphocytes, works in combination with host interferon (IFN)-γ to restore DLA expression.[70] Further, TVT is known to decrease the number of monocytes in the peripheral blood by 40%, and substantially impair the efficiency with which dendritic cells (DCs) are generated from monocytes and with which mature DCs are generated from immature DCs.[71]

Treatment

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

High rate of spontaneous regression warrants proper caution in the evaluation of the success achieved with different therapeutic approaches.[2, 5] Treatment can be attempted by excisional surgery, chemotherapy, radiotherapy, immunotherapy or a combination thereof.

Surgical treatment has been applied since the last century[1, 2] with a low rate of efficacy resulting in a high recurrence rate (between 18 and 60%), influenced by the location and extent of disease; up to 50–68% relapses occurring solely owing to tumour cell transplantation into the surgical wound during traditional surgical intervention.[19, 24, 72, 73] During operating male dogs, care should be taken not to damage the urethra of penis. If the urethral orifice is involved, an in-dwelling catheter should be used till complete healing is accomplished.[2] Scalpel surgery has been condemned as impracticable in cases of generalized CTVT.[74] The use of electrocautery makes the operation easier and seems to be a little more effective. Therefore, surgical excision should be applied to those dogs that present solitary, small, easily accessible and non-invasive tumour nodules. Even in such resectable tumours electrosurgical or cryosurgical excision seems to have an edge over traditional surgical approaches. Voorhees and Babbs[75] advocated adjuvant treatment with hydralazine (0.5 mg/kg i.v.) to increase the temperature difference between TVT and surrounding normal tissues during inductive diathermy. Badylak et al.[76] found CTVT to be resistant to microwave-induced hyperthermia damage and Hazle et al.[77] reported limited success of magnetic resonance imaging-guided high temperature thermal therapy of transplanted TVT in the canine prostate using a directional transurethral ultrasound applicator. However, Schwartz et al.[78] could demonstrate selective and effective photothermal ablation of TVT in brains of mixed breed hounds using near-infrared absorbing nanoshells.

Chemotherapy gives more promising results and up to 100% remission can be achieved. Trials with new generation antineoplastic drugs that started during the 1950s established antimitotic agents as the preferred agents for the treatment of the tumour. An array of chemotherapeutic agents has been tried against CTVT such as cyclophosphamide,[20, 24] methotrexate,[79] cyclophosphamide with prednisone, vinblastine with cyclophosphamide or methotrexate, vincristine,[80] vincristine with doxorubicin, cyclophosphamide with methotrexate and vincristine.[1, 20, 74] Vincristine, which has emerged as the drug of choice for TVT therapy, was included in treatment protocols since the eight decade of the last century.[20, 74, 80, 81]

Many studies suggest a better response with vincristine alone as compared to combined chemotherapy,[2] and currently, the intravenous administration of vincristine sulphate at the dose of 0.025 mg kg−1 of body weight, once a week, for 2 weeks beyond the complete resolution of the gross tumour mass, is the treatment of choice, irrespective of the neoplasm size and extent, the presence of metastases and the duration of the disease (Fig. 2). The animals recover fully, with no impact on behaviour and reproductive ability. Scarpelli et al.[82] observed that larger tumour mass, increased age and therapy during hot and rainy months were unfavourable predictive factors retarding the success of vincristine therapy.

Temporary side effects (partial anorexia and mild depression) may be reported in less than 20% of the treated dogs, usually 1–2 days after vincristine administration. Chemotherapy may cause transient leucopenia, but less than 2% subjects present such a leucopenia that might deserve an adjunctive antibiotic treatment or impose discontinuation of one or more chemotherapeutic administrations. Dogs undergoing therapy with vincristine also exhibit a transient deterioration of semen quality that rapidly returns to normal within 15 days of last injection.[83, 84] Before initiating vincristine chemotherapy it is important to assess the general health condition of the animal, while during therapy it is necessary to follow-up the total number of leukocytes, at least at weekly intervals. Novel approaches for improved and targeted drug delivery have also been attempted.[85] Vilensky et al.[25] evaluated vascular-targeted photodynamic therapy (VTP) using Pd-bacteriopheophorbide (WST09) as an alternative to conventional chemotherapy, and concluded that VTP with WST09 can efficiently treat CTVT in a single session, as compared with four to six sessions of chemotherapy.

TVT has already been proven to be highly sensitive to irradiation from the last century. Solacroup proposed radiation therapy for TVT in Europe in 1950, which has been employed since, mainly in France resulting in a sufficient reduction of TVT cases. Dosage recommendations range from 1500 to 2500 rads (depending on the chronicity and the extension of neoplastic lesions), divided in sessions of 400–500 rads over a period of 1–2 weeks, or a single dose of 1000 rads which, if not curative, can safely be repeated one to four times. However, radiotherapy requires trained personnel, specialized equipment, high expenses and, also, the foregoing necessity to chemically immobilize the dog. Therefore, its use is recommended only in cases where other treatments fail.[86] Intensive radiotherapy or chemotherapy may lead to fatal leukopenia and immunosuppression.[87]

Immunotherapy has also been reported as a method for the treatment of this tumour. While traditional approaches employed convalescent sera and whole blood for transfer of passive immunity, or tumour homogenates as autochthonous vaccine and bacterial toxins for active immunization, modern approaches have used interleukins and viral agents for stimulating active cellular immunity.[88, 89] Hess et al.[90] found intralesional BCG therapy of canine venereal tumours to be highly effective in causing regression. Mukaratirwa et al.[91] reported faster remission with combined BCG and vincristine therapy than vincristine or BCG alone. Co-infection with canine parvovirus influences the course of the disease; when inoculated simultaneously with the tumour at a distant site, a modified-live parvoviral vaccine prevents tumour transplantation. However, the vaccine has no effect if inoculated 3 days after tumour transplantation.[88] Therapy of TVT with plasmid encoded IL-6, IL-12 and IL-15 genes delivered through electroporation has also been suggested.[69, 92, 93] CTVT cells in culture are subject to a growth-repressing effect by sulphur-containing amino acids;[94] therefore, supplementation of diet with such amino acids may also be of value towards faster remission of the tumour. Pai et al.[95] evaluated fused DC/TVT hybrids as a vaccine against TVT and reported substantial inhibition of tumour progression and accelerated regression in the vaccinated group. Successful protection against TVT has also been reported with a Chicken HSP70 DNA vaccine.[96]

Conclusion

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

CTVT represents the oldest known malignant cell in continuous propagation whereby a single malignant clone of cells has colonized dogs worldwide. Clinical history, signalment and cytological features are often sufficient for making diagnosis for CTVT. Biopsy and histological examination are not necessary except cases with an atypical presentation. CTVT is curable in almost all cases with three cycles of vincristine sulphate intravenous injection at the dose rate 0.025 mg kg−1 body weight. The disease is difficult to control owing to the role of stray and wild dogs as reservoirs of infection. Proper examination of animals prior to mating to eliminate animals with patent infection from the breeding population and strict measures against mingling with stray animals will control the disease. Sustained animal birth control programme of stray dogs with chemotherapy of the affected dogs shall definitely decrease CTVT cases to a great extent.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References

The authors acknowledge the anonymous reviewers for their constructive criticism of the manuscript in advance. Financial support received by B. G. in the form of a Junior Research Fellowship from Council of Scientific and Industrial Research (CSIR, India) is also duly acknowledged.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Geographical distribution
  5. Aetiology and transmission
  6. Excitating factors
  7. Clinico-pathological features
  8. Diagnosis
  9. Prognosis
  10. Immunity
  11. Treatment
  12. Conclusion
  13. Conflict of interest
  14. Acknowledgements
  15. References
  • 1
    Boscos CM, Ververidis HN (2004) Canine TVT—Clinical Findings, Diagnosis and Treatment. Proceedings of the 29th World Congress of the World Small Animal Veterinary Association. http://www.vin.com/proceedings/Proceedings.plx?CID=WSAVA2004 [accessed 12 April 2012].
  • 2
    Das U and Das AK. Review of canine transmissible venereal sarcoma. Veterinary Research Communications 2000; 24: 545556.
  • 3
    Meléndez-Zajgla J and Maldonado V. Is cancer a transmittable disease? Gaceta Médica de México 2007; 143: 353354.
  • 4
    Rust JH. Transmissible lymphosarcoma in the dog. Journal of the American Veterinary Medical Association 1949; 114: 1014.
  • 5
    Moulton JE. Tumours of Domestic Animals. 3rd edn., Berkeley, University of California Press, 1990: 498502.
  • 6
    Higgins DA. Observations on the canine transmissible venereal tumour as seen in the Bahamas. The Veterinary Record 1966; 79: 6771.
  • 7
    Tateyama S, Nazaka H, Ashizawa H, Otsyka H, Wada S and Yamoguchi R. Neoplasm in animals studied at Miyazaki University in 1970–1979. Journal of the Japan Veterinary Medical Association 1986; 39: 242247.
  • 8
    Singh P, Singh K, Sharma DK, Behl SM and Chandna IS. A surgery of tumours in domestic animals. The Indian Veterinary Journal 1991; 68: 721725.
  • 9
    Cohen D. The biological behaviour of the transmissible venereal tumour in immunosuppressed dogs. European Journal of Cancer 1973; 9: 253258.
  • 10
    Mukaratirwa S and Gruys E. Canine transmissible venereal tumour: cytogenetic origin, immunophenotype, and immunobiology—a review. The Veterinary Quarterly 2003; 25: 101111.
  • 11
    Marcos R, Santos M, Marrinhas C and Rocha E. Cutaneous transmissible venereal tumor without genital involvement in a prepubertal female dog. Veterinary Clinical Pathology 2006; 35: 106109.
  • 12
    Holmes JM. Measurement of the rate of death of canine transmissible venereal tumour cells transplanted into dogs and nude mice. Research in Veterinary Science 1981; 30: 248250.
  • 13
    Dass LL, Sahay PN, Khan AA and Jha GJ. Malignant transmissible venereal tumour. Canine Practice 1986; 13: 1518.
  • 14
    Karlson AG and Mann FC. The transmissible venereal tumour of dogs: observation of forty generations of experimental transfer. Annals of the New York Academy of Sciences 1952; 54: 11971213.
  • 15
    Leroi AM, Koufopanou V and Burt A. Cancer selection. Nature Reviews Cancer 2003; 3: 226231.
  • 16
    Murgia C, Pritchard JK, Kim SY, Fassati A and Weiss RA. Clonal origin and evolution of a transmissible cancer. Cell 2006; 126: 47787.
  • 17
    Rebbeck CA, Thomas R, Breen M, Leroi AM and Burt A. Origins and evolution of a transmissible cancer. Evolution 2009; 63: 23402349.
  • 18
    Rebbeck CA, Leroi AM and Burt A. Mitochondrial capture by a transmissible cancer. Science 2011; 331: 303.
  • 19
    Pandey SK, Dhawedkar RG and Patel MR. Canine transmissible venereal sarcoma. Clinical trial with autogenous formalized vaccine. The Indian Veterinary Journal 1977; 54: 852853.
  • 20
    Das U, Das AK, Das DK and Das BB. Clinical report on the efficacy of chemotherapy in canine transmissible venereal sarcoma. The Indian Veterinary Journal 1991b; 68: 249252.
  • 21
    Osipov NE and Golubeva VA. Diagnosis and treatment of transmissible sarcoma of dogs. Veterinariia 1976; 7: 9798.
  • 22
    Singh J, Rama JS, Sood N, Pangawkar G and Gupta PP. Clinico-pathological studies on the effect of different antineoplastic chemotherapy regimens on transmissible venereal tumours in dogs. Veterinary Research Communications 1996; 20: 7181.
  • 23
    Hamir AN. Primary penile and nasal transmissible venereal tumour in a dog. Australian Veterinary Journal 1985; 62: 430432.
  • 24
    Pandey SK, Chandpuria VP, Bhargava MK and Tiwari SK. Incidence, treatment, approach and metastasis of canine transmissible venereal sarcoma. The Indian Journal of Animal Sciences 1989; 59: 510513.
  • 25
    Vilensky J, Koudinova NV, Harmelin A, Scherz A and Salomon Y. Vascular-targeted photodynamic therapy (VTP) of a canine-transmissible venereal tumour in a murine model with Pd-bacteriopheophorbide (WST09). Veterinary and Comparative Oncology 2005; 3: 182193.
  • 26
    Harmelin A, Pinthus JH, Katzir N, Kapon A, Volcani Y, Amariglio EN and Rehavi G. Use of a murine xenograft model for canine transmissible venereal tumor. American Journal of Veterinary Research 2001; 62: 907911.
  • 27
    Kabuusu RM, Stroup DF and Fernandez C. Risk factors and characteristics of canine transmissible venereal tumours in Grenada, West Indies. Veterinary and Comparative Oncology 2010; 8: 5055.
  • 28
    Amariglio EN, Hakim I, Brok-Simoni F, Grossman Z, Katzir N, Harmelin A, Ramot B and Rechavi G. Identity of rearranged LINE/c-MYC junction sequences specific for the canine transmissible venereal tumour. Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 81368139.
  • 29
    Brown NO, Calvert C and MacEwen EG. Chemotherapeutic management of transmissible venereal tumour in 30 dogs. Journal of the American Veterinary Medical Association 1980; 176(10 Pt 1): 983986.
  • 30
    Rogers KS. Transmissible venereal tumor. Compendium on Continuing Education for the Practising Veterinarian 1997; 19: 10361045.
  • 31
    Gordon A, Theilen GH and Madewell BR. Veterinary Cancer Medicine. Philadelphia, Lea and Febiger, 1979: 171178.
  • 32
    Mulligan RM. Neoplasm of the Dog. Baltimore, William and Wilkins, 1949: 93.
  • 33
    Parent R, Teuscher E, Morin M and Buyschaert A. Presence of the canine transmissible venereal tumor in the nasal cavity of dogs in the area of Dakar (Senegal). The Canadian Veterinary Journal 1983; 24: 287288.
  • 34
    Papazoglou LG, Koutinas AF, Plevraki AG and Tontis D. Primary intranasal transmissible venereal tumour in the dog: a retrospective study of six spontaneous cases. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine 2001; 48: 391400.
  • 35
    Albanese F, Poli A, Millanta F and Abramo F. Primary cutaneous extragenital canine transmissible venereal tumour with Leishmania-laden neoplastic cells: a further suggestion of histiocytic origin? Veterinary Dermatology 2002; 13: 243246.
  • 36
    Catone G, Marino G, Poglayen G, Gramiccia M, Ludovisi A and Zanghì A. Canine transmissible venereal tumour parasitized by Leishmania infantum. Veterinary Research Communications 2003; 27: 549553.
  • 37
    Levy E, Mylonakis ME, Saridomichelakis MN, Polizopoulou ZS, Psychogios V and Koutinas AF. Nasal and oral masses in a dog. Veterinary Clinical Pathology 2006; 35: 115118.
  • 38
    Batamuzi EK and Kristensen F. Urinary tract infection: the role of canine transmissible venereal tumour. The Journal of Small Animal Practice 1996; 37: 276279.
  • 39
    Liao K, Hung S, Hsiao Y, Bennett M and Chu R. Canine transmissible venereal tumor cell depletion of B lymphocytes: molecule(s) specifically toxic for B cells. Veterinary Immunology and Immunopathology 2003; 92(3–4): 149162.
  • 40
    Mukaratirwa S, Chiwome T, Chitanga S and Bhebhe E. Canine transmissible venereal tumour: assessment of mast cell numbers as indicators of the growth phase. Veterinary Research Communications 2006; 30: 613621.
  • 41
    Yang TJ. Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma (review). Anticancer Research 1988; 8: 9395.
  • 42
    Chu RM, Sun TJ, Yang HY, Wang DG, Liao KW, Chuang TF, Lin CH and Lee WC. Heat shock proteins in canine transmissible venereal tumor. Veterinary Immunology and Immunopathology 2001; 82: 921.
  • 43
    Padovan D, Yang TJ and Fenton MA. Epidural spinal metastasis of canine transmissible venereal sarcoma. Zentralblatt für Veterinärmedizin. Reihe A 1987; 34: 401404.
  • 44
    Ferreira AJ, Jaggy A, Varejão AP, Ferreira ML, Correia JM, Mulas JM, Almeida O, Oliveira P and Prada J. Brain and ocular metastases from a transmissible venereal tumour in a dog. The Journal of Small Animal Practice 2000; 41: 165168.
  • 45
    Paterson AH, Yoxall A, Smith I, Taylor DM and McCready VR. The concentration of 67Ga and 45Ca in the lactating mammary gland and its relevance to the tumor uptake of 67Ga citrate. Cancer Research 1976; 36: 452457.
  • 46
    Forsberg F, Johnson DK, Merton DA, Li JB, Losco PE, Hagen EK and Goldberg BB. Contrast-enhanced transrectal ultrasonography of a novel canine prostate cancer model. Journal of Ultrasound in Medicine 2002; 21: 10031013.
  • 47
    Duncan JR and Prasse KW. Cytology of canine cutaneous round cell tumors. Mast cell tumor, histiocytoma, lymphosarcoma and transmissible venereal tumor. Veterinary Pathology 1979; 16: 673679.
  • 48
    Cockrill JM and Beasley JN. Ultrastructural characteristics of canine transmissible venereal tumor at various stages of growth and regression. American Journal of Veterinary Research 1975; 36: 677681.
  • 49
    Das AK, Das U, Das D and Sengupta J. Histopathological study of canine transmissible venereal tumour. The Indian Veterinary Journal 1990; 67: 473474.
  • 50
    Marchal T, Chabanne L, Kaplanski C, Rigal D and Magnol JP. Immunophenotype of the canine transmissible venereal tumour. Veterinary Immunology and Immunopathology 1997; 57: 111.
  • 51
    Cangul IT (2001) Improved classification, diagnosis and prognosis of canine round cell tumours. http://www.vetscite.org/publish/articles/000038/article.html [accessed 11 April 2012].
  • 52
    Wright DH, Peel S, Cooper EH and Hughes DT. Transmissible venereal sarcoma of dogs. A histochemical and chromosomal analysis of tumours in Uganda. Revue Européenne D'études Cliniques et Biologiques 1970; 15: 155160.
  • 53
    Adams EW and Slaughter LJ. A canine venereal tumor with metastasis to the brain. Pathologia Veterinaria Online 1970; 7: 498532.
  • 54
    Thomas R, Rebbeck C, Leroi AM, Burt A and Breen M. Extensive conservation of genomic imbalances in canine transmissible venereal tumors (CTVT) detected by microarray-based CGH analysis. Chromosome Research 2009; 17: 927934.
  • 55
    Palker TJ and Yang TJ. Identification and physicochemical characterization of a tumor-associated antigen from canine transmissible venereal sarcoma. Journal of the National Cancer Institute 1981; 66: 779787.
  • 56
    Yang TJ, Palker TJ and Harding MW. Tumor size, leukocyte adherence inhibition and serum levels of tumor antigen in dogs with the canine transmissible venereal sarcoma. Cancer Immunology, Immunotherapy 1991; 33: 255262.
  • 57
    Katzir N, Arman E, Cohen D, Givol D and Rechavi G. Common origin of transmissible venereal tumors (TVT) in dogs. Oncogene 1987; 1: 445448.
  • 58
    Choi YK and Kim CJ. Sequence analysis of canine LINE-1 elements and p53 gene in canine transmissible venereal tumor. Journal of Veterinary Science 2002; 3: 285292.
  • 59
    Vázquez-Mota N, Simón-Martínez J, Córdova-Alarcon E, Lagunes L and Fajardo R. The T963C mutation of TP53 gene does not participate in the clonal origin of canine TVT. Veterinary Research Communications 2008; 32: 187191.
  • 60
    de Brito CP, de Oliveira CM, Soares FA, Faustino M and de Oliveira CA. Immunohistochemical determination of estrogen receptor-alpha in vaginal and tumor tissues of healthy and TVT-affected bitches and their relation to serum concentrations of estradiol-17beta and progesterone. Theriogenology 2006; 66: 15871592.
  • 61
    Harmelin A, Zuckerman A and Nyska A. Correlation of Ag-NOR protein measurements with prognosis in canine transmissible venereal tumour. Journal of Comparative Pathology 1995; 112: 429433.
  • 62
    Mukaratirwa S, Chimonyo M, Obwolo M, Gruys E and Nederbragt H. Stromal cells and extracellular matrix components in spontaneous canine transmissible venereal tumour at different stages of growth. Histology and Histopathology 2004; 19: 11171123.
  • 63
    De Monbreun WA and Goodpasture EW. An experimental investigation concerning the nature of contagious lymphosarcoma in dogs. American Journal of Cancer 1934; 21: 295321.
  • 64
    Powers RD. Immunologic properties of canine transmissible venereal sarcoma. American Journal of Veterinary Research 1968; 29: 16371645.
  • 65
    Cohen D. The transmissible venereal tumor of the dog—a naturally occurring allograft? A review. Israel Journal of Medical Sciences 1978; 14: 1419.
  • 66
    Mizuno S, Fujinaga T, Tajima M, Otomo K and Koike T. Role of lymphocytes in dogs experimentally re-challenged with canine transmissible sarcoma. Nippon Juigaku Zasshi 1989; 51: 8695.
  • 67
    Cohen D. In vitro cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity to the transmissible venereal tumor of the dog. Journal of the National Cancer Institute 1980; 64: 317321.
  • 68
    Hsiao YW, Liao KW, Hung SW and Chu RM. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. Journal of Immunology 2004; 172: 15081514.
  • 69
    Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC and Chu RM. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Letters 2008; 272: 285295.
  • 70
    Hsiao YW, Liao KW, Chung TF, Liu CH, Hsu CD and Chu RM. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunology, Immunotherapy 2008; 57: 10911104.
  • 71
    Liu CC, Wang YS, Lin CY, Chuang TF, Liao KW, Chi KH, Chen MF, Chiang HC and Chu RM. Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor. Cancer Immunology, Immunotherapy 2008; 57: 479491.
  • 72
    Dass LL and Sahay PN. Surgical treatment of canine transmissible venereal tumour a retrospective study. The Indian Veterinary Journal 1989; 66: 255258.
  • 73
    Panchbhai VS, Karpe G, Kulkarni GB and Kulkarni SK. Use of autogenous vaccine in transmissible canine venereal tumour. The Indian Veterinary Journal 1990; 67: 983984.
  • 74
    Das AK, Das U and Das DK. A clinical report on the efficacy of vincristine on canine transmissible venereal sarcoma. The Indian Veterinary Journal 1991a; 68: 575576.
  • 75
    Voorhees WD 3rd and Babbs CF. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. European Journal of Cancer & Clinical Oncology 1982; 18: 10271033.
  • 76
    Badylak SF, Babbs CF, Skojac TM, Voorhees WD and Richardson RC. Hyperthermia-induced vascular injury in normal and neoplastic tissue. Cancer 1985; 56: 9911000.
  • 77
    Hazle JD, Diederich CJ, Kangasniemi M, Price RE, Olsson LE and Stafford RJ. MRI-guided thermal therapy of transplanted tumors in the canine prostate using a directional transurethral ultrasound applicator. Journal of Magnetic Resonance Imaging 2002; 15: 409417.
  • 78
    Schwartz JA, Shetty AM, Price RE, Stafford RJ, Wang JC, Uthamanthil RK, Pham K, McNichols RJ, Coleman CL and Payne JD. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Research 2009; 69: 16591667.
  • 79
    Theilen GH and Madewell BR. Clinical Application of cancer chemotherapy. In: Veterinary Cancer Medicine. 2nd edn., Philadelphia, Lea and Febiger, 1987: 183196.
  • 80
    Calvert CA, Leifer CE and MacEwen EG. Vincristine for treatment of transmissible venereal tumour in the dogs. Journal of the American Veterinary Medical Association 1982; 181: 163164.
  • 81
    Amber EI, Henderson RA, Adeyanju JB and Gyang EO. Single-drug chemotherapy of canine transmissible venereal tumour with cyclophosphamide, methotrexate, or vincristine. Journal of Veterinary Internal Medicine 1990; 4: 144147.
  • 82
    Scarpelli KC, Valladão ML and Metze K. Predictive factors for the regression of canine transmissible venereal tumor during vincristine therapy. Veterinary Journal 2010; 183: 362363.
  • 83
    Saratsis P, Ypsilantis P and Tselkas K. Semen quality during vincristine treatment in dogs with transmissible venereal tumor. Theriogenology 2000; 53: 11851192.
  • 84
    Gobello C and Corrada Y. Effects of vincristine treatment on semen quality in a dog with a transmissible venereal tumour. The Journal of Small Animal Practice 2002; 43: 416417.
  • 85
    Stettner N, Brenner O, Eilam R and Harmelin A. Pegylated liposomal doxorubicin as a chemotherapeutic agent for treatment of canine transmissible venereal tumor in murine models. Journal of Veterinary Medical Science 2005; 67: 11331139.
  • 86
    Rogers KS, Walker MA and Dillon HB. Transmissible venereal tumour: a retrospective study of 29 cases. Journal of the American Animal Hospital Association 1998; 34: 463470.
  • 87
    Epstein RB and Sarpel SC. Autologous bone marrow infusion following high dose chemotherapy of the canine transmissible venereal tumor (TVT). Experimental Hematology 1980; 8: 683689.
  • 88
    Yang TJ. Parvovirus-induced regression of canine transmissible venereal sarcoma. American Journal of Veterinary Research 1987; 48: 799800.
  • 89
    Den Otter W, Cadée J, Gavhumende R, De Groot CJ, Hennink WE and Stewart R. Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour. Cancer Immunology, Immunotherapy 1999; 48: 419420.
  • 90
    Hess AD, Catchatourian R, Zander AR and Epstein RB. Intralesional Bacillus Calmette–Guérin immunotherapy of canine venereal tumors. Cancer Research 1977; 37: 39903994.
  • 91
    Mukaratirwa S, Chitanga S, Chimatira T, Makuleke C, Sayi ST and Bhebhe E. Combination therapy using intratumoral bacillus Calmette–Guerin (BCG) and vincristine in dogs with transmissible venereal tumours: therapeutic efficacy and histological changes. Journal of the South African Veterinary Association 2009; 80: 9296.
  • 92
    Chou PC, Chuang TF, Jan TR, Gion HC, Huang YC, Lei HJ, Chen WY and Chu RM. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles. Veterinary Immunology and Immunopathology 2009; 130(1–2): 2534.
  • 93
    Chuang TF, Lee SC, Liao KW, Hsiao YW, Lo CH, Chiang BL, Lin XZ, Tao MH and Chu RM. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. International Journal of Cancer 2009; 125: 698707.
  • 94
    Prier JE and Brodey RS. Canine neoplasia. A prototype for human cancer study. Bulletin of the World Health Organization 1963; 29: 331344.
  • 95
    Pai CC, Kuo TF, Mao SJ, Chuang TF, Lin CS and Chu RM. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Veterinary Immunology and Immunopathology 2011; 139: 187199.
  • 96
    Yu WY, Chuang TF, Guichard C, El-Garch H, Tierny D, Laio AT, Lin CS, Chiou KH, Tsai CL, Liu CH, Li WC, Fischer L and Chu RM. Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model. Vaccine 2011; 29: 34893500.